Dazucorilant

Corcept Therapeutics announced DAZALS study results, a Phase 2 trial for dazucorilant in ALS patients, which didn't meet its primary endpoint on ALSFRS-R change. However, the 300 mg group saw no deaths vs. 5 in placebo. The long-term extension study continues, with overall survival assessment in March 2025. Dazucorilant has FDA Fast Track Designation.

Corcept Therapeutics announced DAZALS study results, a Phase 2 trial for dazucorilant in ALS patients, which did not meet its primary endpoint. However, fewer deaths were observed in the 300 mg dazucorilant group compared to placebo. The long-term extension study continues, with overall survival to be assessed in March 2025.

Corcept Therapeutics reports Q3 2024 revenue of $182.5M, up 48% YoY, and increases 2024 revenue guidance to $675-$700M. Net income per share is $0.41 (diluted), with cash and investments at $547.6M. The company plans to submit an NDA for relacorilant this quarter, supported by Phase 3 GRADIENT trial results.